Takada, K., Kashiwagi, S., Goto, W., Asano, Y., Takahashi, K., Takashima, T., . . . Ohira, M. (2018). Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med.
Citação norma ChicagoTakada, Koji, et al. "Use of the Tumor-infiltrating CD8 to FOXP3 Lymphocyte Ratio in Predicting Treatment Responses to Combination Therapy With Pertuzumab, Trastuzumab, and Docetaxel for Advanced HER2-positive Breast Cancer." J Transl Med 2018.
Citação norma MLATakada, Koji, et al. "Use of the Tumor-infiltrating CD8 to FOXP3 Lymphocyte Ratio in Predicting Treatment Responses to Combination Therapy With Pertuzumab, Trastuzumab, and Docetaxel for Advanced HER2-positive Breast Cancer." J Transl Med 2018.